Education
About Us
Working with TipRanks
Follow Us
Zymeworks (ZYME)
:ZYME
ZYME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.21 - $17.70
Previous CloseN/A
Volume35.38K
Average Volume (3M)431.14K
Market Cap
$890.11M
Enterprise Value$738.97M
Total Cash (Recent Filing)$225.78M
Total Debt (Recent Filing)$18.51M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Jul 31, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding69,683,495
10 Day Avg. Volume426,354
30 Day Avg. Volume431,137
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)2.53
Price to Sales (P/S)0.00
P/FCF Ratio-6.98
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.94
Enterprise Value/Gross Profit21.31
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$23.80Price Target Upside87.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Zymeworks News
Bulls Say, Bears Say
Bulls Say
Financial MilestonesZymeworks is entitled to receive a $20M milestone payment in connection with the NMPA approval of zanidatamab, and is eligible to receive up to $144M in additional development and commercial milestones.
Financial StabilityThe company's balance sheet is strong enough to support operations well into the future, providing financial stability.
Regulatory ApprovalZanidatamab approved in China, modestly ahead of schedule.
Bears Say
Clinical RisksRisks to our thesis include: clinical trial failures due to safety issues, clinical setbacks due to insufficient efficacy, and possible long-term dilution risk.
Competitive LandscapeFRα-targeting ADC presentations provide a reminder of the crowded competitive landscape ZW191 will need to navigate.
Investor SentimentShort interest is 9.7% of float, indicating some level of skepticism from investors.
Ownership Overview
25.61% Insiders
7.49% Mutual Funds
0.71% Other Institutional Investors
51.36% Public Companies and Individual Investors
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $8.21 and its highest was $17.70 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $890.11M.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Jul 31, 2025 which is in 44 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on May 08, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.684 by $0.384.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.49.
How many shares outstanding does Zymeworks have?
Zymeworks has 69,683,495 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.684. Following the earnings report the stock price went down -0.177%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in ZYME
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.80 (87.85% Upside)
$23.80 (87.85% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 401.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.07%
12-Months-Change
Fundamentals
Return on Equity
-29.80%
Trailing 12-Months
Asset Growth
-23.16%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with significant revenue growth, strategic partnerships, and a strong cash position outweighing the increased operating expenses.Read More>ZYME Stock 12 Month Forecast
Average Price Target
$23.80
▲(87.85%Upside)
Technical Analysis
Arcus Biosciences
―
Vir Biotechnology
―
Nurix Therapeutics
―
Pharvaris
―
Mineralys Therapeutics, Inc.
―